Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 10/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16398861 | 0.86 | MRGPRX4 (0.65) | POLBL3MBTL1ALDH1A1MRGPRX4MAPT | |
| SCHEMBL24400852 | 0.83 | ALDH1A1 (0.54) | POLBL3MBTL1ALDH1A1MRGPRX4MAOB | |
| SCHEMBL31395021 | 0.83 | POLB (0.53) | POLBL3MBTL1ALDH1A1MRGPRX4MAPT | |
| SCHEMBL12517068 | 0.82 | MAPT (0.68) | POLBL3MBTL1ALDH1A1MRGPRX4MAPT | |
| SCHEMBL31395099 | 0.82 | MAPT (0.68) | POLBL3MBTL1ALDH1A1MRGPRX4MAPT | |
| SCHEMBL3040045 | 0.81 | SLC2A1 (0.57) | MRGPRX4SLC2A1MAOBIDO1MAOA | |
| SCHEMBL3037641 | 0.80 | MRGPRX4 (0.57) | POLBL3MBTL1MRGPRX4MAPTSLC2A1 | |
| SCHEMBL876853 | 0.80 | L3MBTL1 (1.00) | POLBL3MBTL1ALDH1A1MAPT | |
| SCHEMBL16762095 | 0.80 | MRGPRX4 (0.53) | POLBL3MBTL1ALDH1A1MRGPRX4MAPT | |
| SCHEMBL3042303 | 0.80 | MRGPRX4 (0.74) | L3MBTL1MRGPRX4SLC2A1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102387704-A | Agonists and antagonists of the S1P5 receptor, and methods of uses thereof | ABBOTT LAB | 2012-03-21 | — | — | CN | disclosed |
| EP-2395835-A1 | AGONISTS AND ANTAGONISTS OF THE SIP5 RECEPTOR, AND METHODS OF USES THEREOF | Abbott Laboratories (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | S1PR5, LPAR5, S1PR1 | POLB 4840/4885L3MBTL1 2701/4885ALDH1A1 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.